Infilbray (venglustat) was approved by the FDA on November 18, 2026 to treat the neurological symptoms of Type 3 Gaucher disease, the 54th novel drug approval of 2026 on the FDA's Novel Drug Approvals list.
Verified against: FDA action day November 18, 2026 (FDA News Release) · Goal date: none on record.
This page was first committed to pdufa.bio's public repository on Nov 20, 2026, 4:09 AM ET (public commit 2b423a8). Dates on this page are the FDA's and the sponsor's; this line is ours.
The FDA approved Infilbray (venglustat) tablets on November 18, 2026, the first treatment for the neurological symptoms of Type 3 Gaucher disease, in adults and children weighing at least 15 kg.
The FDA's news release states that on November 18, 2026 it approved Infilbray (venglustat) tablets for the neurological symptoms of Type 3 Gaucher disease (GD3) in adults and pediatric patients weighing at least 15 kg, and that the approval was granted to Genzyme Corporation, a Sanofi company (FDA, November 18, 2026). Per the FDA, a randomized, double-blind, multicenter study enrolled 43 patients aged 12 and older with GD3 who had been stabilized on enzyme replacement therapy; patients took Infilbray once daily by mouth or intravenous enzyme replacement therapy every two weeks for 52 weeks, and at Week 52 the Infilbray group improved on a measure combining ataxia and cognitive assessments compared with the enzyme replacement therapy group. The FDA lists gastrointestinal symptoms and mood effects as the most frequent side effects and reports serious psychiatric risks including suicidal ideation and behavior. The application had Orphan Drug designation and Priority Review. We hold no publicly disclosed PDUFA goal date for this application, so it was never a dated event on our calendar.
Run-up figures are the stock's own daily closing path over the 120 trading days before the decision, from our price history. Cohort move is the historical median absolute decision-day move for this market-cap tier. History, not a prediction.
Primary source: FDA News Release, November 18, 2026
FDA record of the action: the FDA approved on November 18, 2026, per FDA News Release, November 18, 2026 (FDA notice). The sponsor announced it the same day. Action dates on pdufa.bio come from the FDA's own record, not the press release. Every FDA action we hold, by FDA date: FDA approval letters.
Yes. On November 18, 2026 the FDA approved Infilbray (venglustat) tablets for the neurological symptoms of Type 3 Gaucher disease in adults and pediatric patients weighing at least 15 kg, per the FDA's own news release. The FDA calls it the first treatment for the neurological symptoms of Type 3 Gaucher disease. The approval was granted to Genzyme Corporation, a Sanofi company.
Infilbray (venglustat) is a Sanofi (SNY) program. The FDA decision came on November 18, 2026; the FDA's own record of the decision is linked on this page.
SNY moved -0.9%, measured as the 2026-11-18 close against the 2026-11-17 close. It is one trading day's move, so it can include news other than the decision. Historical measurement, not a prediction, and not investment advice.
Per the FDA, a randomized, double-blind study of 43 patients aged 12 and older with Type 3 Gaucher disease who had been stabilized on enzyme replacement therapy. Patients took Infilbray once daily by mouth or continued intravenous enzyme replacement therapy every two weeks for 52 weeks; at Week 52 the Infilbray group improved on a measure combining ataxia and cognitive assessments compared with the enzyme replacement therapy group.
We hold no publicly disclosed goal date for it, so it was not a dated event on our calendar. The FDA's release says the application had Priority Review and Orphan Drug designation.